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ABSTRACT
Objective: To discuss the requirement from the 
National Health Surveillance Agency (ANVISA), for assisted 
reproduction treatment patients to undergo laboratory 
tests for ZIKV detection, and if the public health authorities 
and government leaders’ recommendations to women 
simply avoid pregnancy is prudent.
Methods: This study was performed in a university-
affiliated in vitro fertilization center in Brazil. We present a 
critical discussion on the risk of microcephaly due to ZIKV 
infection and the prevalence of other harmful pathogens 
to vulnerable pregnant women and infants. We assessed, 
954 patients undergoing intracytoplasmic sperm injection 
cycles (ICSI), between April and November of 2016, 
concerning the results of ZIKV test, according to different 
regions in Brazil.
Results: Patients undergoing ICSI cycles were split 
into groups, according to their region of origin: 28 (3.0%) 
were from the North, 27 (2.8%) were from the Northeast, 
40 (4.2%) were from the Midwest, 830 (87.2%) were 
from the Southeast, and 29 (3.0%) were from the South. 
Concerning the diagnosis, 112 samples had a positive 
or inconclusive result for ZIKV, by chromatography 
immunoassay. These samples were re-analyzed by ELISA 
and no result was positive. All positive results were from 
the Southeast region and none from the Northeast or 
Midwest regions, which are considered endemic regions.
Conclusion: ZIKV test before the onset of assisted 
reproduction treatments does not rule out the risk of the 
infection during pregnancy. In addition, although ZIKV 
infection risk is extremely high, the microcephaly risk due 
to ZIKV is not higher than the risk of miscarriage and birth 
defects due to other recognized pathogens.
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INTRODUCTION
Originally discovered in 1947, Zika virus (ZIKV), 
received special attention since cases of microcephaly 
were reported following a 2015 outbreak in Brazil (Fauci 
& Morens, 2016). For half a century, fewer than 20 human 
infections were documented (Faye et al., 2014). The first 
reported outbreak of Zika fever occurred in 2007 on the 
Western Pacific island of Yap in the Federated States of 
Micronesia (Duffy et al., 2009); this was followed by a 
larger epidemic in the French Polynesia, in the South Pacific 
in 2013 and 2014 (Cao-Lormeau et al., 2014). In 2015, 
ZIKV emerged in the Americas, and in 2016 ZIKV infection 
was reported in more than 20 countries or territories in 
South, Central, and North America (Campos et al., 2015; 
Zanluca et al., 2015; Enfissi et al., 2016; Hennessey et 
al., 2016).
Zika virus is predominantly spread via the Aedes species 
of mosquitos; however, other forms of transmission, 
including blood transfusion and probable sexual and 
perinatal transmission, have been reported (Lanciotti et 
al., 2008; Besnard et al., 2014; Musso et al., 2014; 2015). 
Because of its association with congenital defects in 
the form of primary or congenital microcephaly (Vargas et 
al., 2001), as well as with paralytic neuropathy symptoms 
of Guillain-Barré syndrome (Willison et al., 2016), the 
World Health Organization (WHO) has declared ZIKV to 
be a Public Health Emergency of International Concern on 
February 1, 2016 (Heymann et al., 2016).
Much of the concern surrounding ZIKV has focused 
on the link between infection in pregnancy and fetal 
microcephaly, and therefore several long-standing 
complications for both child and the family. In fact, until 
May of 2016, 7,438 suspected microcephaly cases have 
been reported in Brazil since ZIKV emerged (1,326 
confirmed/4,005 investigated) (Lessler et al., 2016; 
Victora et al., 2016). Quantifying the risk of microcephaly 
has been complicated by the uncertainty in the number 
of ZIKV affected pregnancies, owing to the large fraction 
of cases that are asymptomatic, a lack of consensus on 
the definition of microcephaly, and other infectious causes 
of microcephaly, such as cytomegalovirus and rubella 
(Lessler et al., 2016).
Although a causal association of ZIKV infection with 
microcephaly in newborns has not been confirmed, ZIKV 
introduction in Northeastern Brazil is associated with an 
increase in congenital malformations in newborns in the 
same period (Brazilian Health Ministry, 2016).
In a recent statement, the WHO confirms that ZIKV 
is “spreading explosively” and that the associated level 
of concern is “extremely high”. This was followed by the 
declaration (February 2, 2016) of public health emergency 
of international concern around the current outbreak. 
Moreover, the CDC Emergency Operations Center elevated 
their response to ZIKV to level 1, the highest level of 
activation - for only the fourth time in the history of the 
organization. In addition, public health authorities and 
government leaders in multiple countries have issued 
first-ever recommendations for women to simply avoid 
pregnancy.
Moreover, the Brazilian Ministry of Health described 
that cases of ZIKV infection have been confirmed by 
laboratorial tests throughout the whole country (Brazilian 
Health Ministry, 2015). Additionally, with the symptoms 
resulting from the infection, the presence of the virus 
in pregnant women has been associated with cases of 
microcephaly and deaths of newborns. The presumed 
correlation between the infection of pregnant women 
by ZIKV and cases of microcephaly is suggested by the 
neurotropic character of the virus, which was not found in 
other organs of the fetus (Mlakar et al., 2016).
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The laboratorial investigation for suspected cases 
of ZIKV infection includes nonspecific diagnosis and the 
specific diagnosis, which is based on the in vitro detection 
of viral RNA, by molecular biology techniques or by the 
detection of antibodies anti ZIKV, from blood samples.
Therefore, the National Health Surveillance Agency 
(ANVISA), Collegiate Board Resolution #72/2016, 
established that assisted reproduction treatment patients 
must undergo laboratory tests for the detection of the 
antibody against ZIKV (IgM), in serum or plasma sample. 
If the result is reactive or inconclusive, the serological test 
(IgM) must be repeated, within at least 30 days, or the 
laboratorial test by molecular biology should be performed 
according to the assisted reproduction center protocol. 
For male patients, if the result is positive, tests must be 
carried out in sperm samples.
If the test result is “Non-reactive”, together with the 
absence of classical and neurological signs and symptoms 
of ZIKV infection, the controlled ovarian stimulation 
procedure can be initiated for ovum pickup.
The goal of the present study is to discuss whether 
the requirement of the National Health Surveillance 
Agency (ANVISA), to assisted reproduction treatment 
patients undergo laboratory tests for the detection of ZIKV 
makes sense, and if the recommendation of public health 
authorities and government leaders to women simply 
avoid pregnancy, is a prudent recommendation, based 
on the prevalence of other potentially harmful agents for 
pregnant women.
MATERIALS AND METHODS
This study was performed in a university-affiliated 
in vitro fertilization center in Brazil, in which the issue 
concerning the ZIKV infection in pregnant women is a real 
problem, with drastic consequences for the reproductive 
population and assisted reproduction centers. Considering 
the fast spread of ZIKV worldwide, we carry out a critical 
discussion on the risk of microcephaly due to ZIKV 
infection, and prevalence of other harmful pathogens to 
vulnerable pregnant women and infants.
We had 954 intracytoplasmic sperm injection cycles 
(ICSI), performed between April and November of 2016, 
evaluated concerning the results of ZIKV test, according to 
the region of Brazil: North, Northeast, Midwest, Southeast, 
and South.
The ZIKV test was performed by chromatography 
immunoassay (Tellmefast, Biocan©, Coquitlam BC, 
Canada). The test is a qualitative lateral flow immunoassay 
for the simultaneous detection and differentiation of IgG 
and IgM antibodies to ZIKV in human serum. If the test 
results came positive a second test by enzyme linked 
immunosorbent assay (ELISA, Eco Diagnóstica, Vale do 
Sereno, Brazil), was performed. If the ELISA test came 
positive a PCR would be performed.
RESULTS
When patients undergoing ZIKV tests, for ICSI cycles, 
were split into groups according with region of origin 
we observed that: 28 (3%) were from the North, 27 
(2.8%) were from the Northeast, 40 (4.2%) were from 
the Midwest, 830 (87.2%) were from Southeast, and 29 
(3.0%) were from the South.
Concerning diagnosis, 112 (11.7%) samples had a 
positive or inconclusive result from the chromatography 
immunoassay. These samples were re-analyzed using 
ELISA and none came back positive.
All positives results were from the Southeast region 
and none from the Northeast or Midwest regions, which 
are considered endemic regions (Table 1).
Given that other infectious agents may also be 
potentially harmful for pregnant women, the most 
prevalent diseases during pregnancy in Brazil, according to 
epidemiologic data, are summarized in Table 2.
DISCUSSION
Undoubtedly, ZIKV infection risk deserves special 
attention, however, the big question is: infection with 
ZIKV during pregnancy leads to higher risks than other 
previously known pathogens?”.
Pregnant women are exposed to many infectious 
agents that are potentially harmful. Intrauterine bacterial 
infection, such as: Chlamydia trachomatis, Neisseria 
gonorrhea, Treponema pallidum (Syphilis); viral infections, 
such as: Parvovirus B19, Cytomegalovirus, Varicella 
zoster (chickenpox), Herpes Simplex Virus; and parasitic 
infections, such as: Trypanosoma cruzi (Chagas disease), 
Toxoplasma gondii, and Plasmodium falciparum (Malaria), 
may represent major risks for pregnant women and fetus.
Investigators studying the 2013-2014 ZIKV outbreak in 
the French Polynesia estimated that the risk of microcephaly 
due to ZIKV infection in the first trimester of pregnancy 
was 0.95% and recently, the magnitude of the risk of 
microcephaly in Brazil is estimated to be approximately 
0.88% (Johansson et al., 2016).
In fact, the microcephaly risk due to ZIKV infection is 
extremely high; however, it is not higher than the risk of 
other recognized pathogens.
Another important question raised here is about the 
ZIKV test usefulness for assisted reproduction patients, 
and weather this may avoid the microcephaly due to 
ZIKV infection. Our findings demonstrated that the ZIKV 
infection in patients undergoing assisted reproduction 
treatments in a center in the Southeast is null, even when 
performed in patients from endemic regions (Midwest and 
the Northeast). This shows that during this short period 
of time, between the test diagnosis and beginning of 
treatment, the patient may not be infected; however, how 
to ensure that the infection will not occur in the following 
months?
  Table 1. Distribution of ZIKV testes by Chromatography immunoassay and ELISA in the five Brazilian regions.
Region N % Chromatography immunoassay test ELISA test
North 28 3.0 0 0
Northeast 27 2.8 0 0
Midwest 40 4.2 0 0
Southeast 830 87.0 112 0
South 29 3.0 0 0
Total 954 100 112 0
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  Table 2. The prevalence of bacterial, viral and parasitic infections during pregnancy.
Type Pathogens Prevalence Reference
Bacteria
Chlamydia trachomatis 2.57% (Mylonas, 2012)
Neisseria gonorrhea 0.7% to 7%, (Rao et al., 2008)
Neisseria gonorrhea (risk group) 15 - 35% (Benzaken et al., 2006)
Treponema pallidum 0.71% (Gottlieb et al., 2008)
Herpes Simplex Virus 2% (Brown et al., 2005)
Parasites
Trypanosoma cruzi 1% to 40% (Martins-Melo et al., 2014)
Toxoplasma gondii 8% - 22% (Hill & Dubey, 2016)
Plasmodium falciparum 2.9% (Kourtis et al., 2014)
Virus
Parvovirus B19 (endemic period) 1.5% (Valeur-Jensen et al., 1999)
Parvovirus B19 (epidemic period) 13.0% (Valeur-Jensen et al., 1999)
Cytomegalovirus 0.3% (Preece et al., 1986)
Varicella Zoster 0.16% - 0.46% (Helmuth et al., 2015)
ZIKV 0.88% (Johansson et al., 2016)
On the other hand, those patients who are already 
experiencing stress arising from the diagnosis of infertility 
and the decision to undergo an assisted reproduction 
treatment, also suffer from the stress of performing the 
ZIKV test. The instruction to perform the ZIKV associated 
with the alarming news coming from the media makes 
these patients even more frightened and stressed.
In conclusion, we believe that ZIKV test before 
the beginning of assisted reproduction treatments, as 
established by the National Health Surveillance Agency 
(ANVISA), Collegiate Board Resolution #72/2016, does 
not rule out the risk of such infection during pregnancy. 
In addition, although ZIKV infection risk is extremely high, 
especially in endemic regions, the microcephaly risk due to 
ZIKV is not higher than the risk of miscarriage and birth 
defects due to other recognized pathogens. Therefore, 
it is prudent to take precautions to avoid ZIKV as any 
other infection during pregnancy, and more importantly, 
pregnant women or those who wish to become pregnant 
naturally or through assisted reproductive techniques, 
should stay away from alarming news that takes away the 
peace of their pregnancies.
CONFLICT OF INTERESTS
The authors have no conflict of interests to report.
Corresponding author:
Edson Borges Jr.
Fertility - Medical Group, São Paulo, SP - Brazil
E-mail: edson@fertility.com.br
REFERENCES
Benzaken AS, Galban EG, Antunes W, Dutra JC, Peel-
ing RW, Mabey D, Salama A. Diagnosis of gonococ-
cal infection in high risk women using a rapid test. 
Sex Transm Infect. 2006;82:v26-8. PMID: 17118954 
DOI: 10.1136/sti.2006.022566
Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Mus-
so D. Evidence of perinatal transmission of Zika virus, 
French Polynesia, December 2013 and February 2014. 
Euro Surveill. 2014;19:pii:20751. PMID: 24721538 
DOI: 10.2807/1560-7917.ES2014.19.13.20751
Brazil. Brazilian Health Ministry. Ministério da Saúde divul-
ga boletim epidemiológico. 2015.
Monitoring of cases of dengue. Portal da Saúde; 2015 [cit-
ed 2016 Dec 5]. Available at: http://portalsaude.saude.
gov.br/index.php/oministerio/principal/secretarias/svs/
zika
Brazil. Brazilian Health Ministry. Chikungunya fever and 
fever by Zika virus. Epidemiol Week. 2016, 5 [cited 2016 
Dec 5]. Available at: http://combateaedes.saude.gov.br/
images/pdf/Informe_Epidemiologico_12_SE_05_2016.pdf
Brown ZA, Gardella C, Wald A, Morrow RA, Co-
rey L. Genital herpes complicating pregnancy. Ob-
stet Gynecol. 2005;106:845-56. PMID: 16199646 
DOI: 10.1097/01.AOG.0000180779.35572.3a
Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, 
Bahia, Brazil. Emerg Infect Dis. 2015;21:1885-6. PMID: 
26401719 DOI: 10.3201/eid2110.150847
Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, 
Mallet HP, Sall AA, Musso D. Zika virus, French polynesia, 
South pacific, 2013. Emerg Infect Dis. 2014;20:1085-6. 
PMID: 24856001 DOI: 10.3201/eid2006.140138
Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lan-
ciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, 
Guillaumot L, Griggs A, Bel M, Lambert AJ, Laven J, Kosoy 
O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB. Zika vi-
rus outbreak on Yap Island, Federated States of Microne-
sia. N Engl J Med. 2009;360:2536-43. PMID: 19516034 
DOI: 10.1056/NEJMoa0805715
Enfissi A, Codrington J, Roosblad J, Kazanji M, Rousset D. Zika 
virus genome from the Americas. Lancet. 2016;387:227-8. 
PMID: 26775124 DOI: 10.1016/S0140-6736(16)00003-9
Fauci AS, Morens DM. Zika Virus in the Americas-Yet An-
other Arbovirus Threat. N Engl J Med 2016;374:601-4. 
PMID: 26761185 DOI: 10.1056/NEJMp1600297
211Running title: Zika Virus Outbreak - Borges Jr, E.
JBRA Assist. Reprod. | v.21 | no3| July-Aug-Sept/ 2017
Faye O, Freire CC, Iamarino A, Faye O, de Oliveira JV, 
Diallo M, Zanotto PM, Sall AA. Molecular evolution of 
Zika virus during its emergence in the 20(th) centu-
ry. PLoS Negl Trop Dis. 2014;8:e2636. PMID: 24421913 
DOI: 10.1371/journal.pntd.0002636
Gottlieb SL, Pope V, Sternberg MR, McQuillan GM, Beltra-
mi JF, Berman SM, Markowitz LE. Prevalence of syphilis 
seroreactivity in the United States: data from the Nation-
al Health and Nutrition Examination Surveys (NHANES) 
2001-2004. Sex Transm Dis. 2008;35:507-11. PMID: 
18356772 DOI: 10.1097/OLQ.0b013e3181644bae
Helmuth IG, Poulsen A, Suppli CH, Mølbak K. Varicella in 
Europe-A review of the epidemiology and experience with 
vaccination. Vaccine. 2015;33:2406-13. PMID: 25839105 
DOI: 10.1016/j.vaccine.2015.03.055
Hennessey M, Fischer M, Staples JE. Zika Virus Spreads 
to New Areas - Region of the Americas, May 2015-January 
2016. MMWR Morb Mortal Wkly Rep. 2016;65:55-8. PMID: 
26820163 DOI: 10.15585/mmwr.mm6503e1
Heymann DL, Hodgson A, Sall AA, Freedman DO, Staples 
JE, Althabe F, Baruah K, Mahmud G, Kandun N, Vascon-
celos PF, Bino S, Menon KU. Zika virus and microcephaly: 
why is this situation a PHEIC? Lancet. 2016;387:719-21. 
PMID: 26876373 DOI: 10.1016/S0140-6736(16)00320-2
Hill DE, Dubey JP. Toxoplasma gondii as a Parasite in Food: 
Analysis and Control. Microbiol Spectr 2016;4. PMID: 
27726776 DOI: 10.1128/microbiolspec.PFS-0011-2015
Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, 
Gilboa SM, Hills SL. Zika and the Risk of Microceph-
aly. N Engl J Med. 2016;375:1-4. PMID: 27222919 
DOI: 10.1056/NEJMp1605367
Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. 
N Engl J Med. 2014;370:2211-8. PMID: 24897084 DOI: 
10.1056/NEJMra1213566
Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, 
Johnson AJ, Stanfield SM, Duffy MR. Genetic and serologic 
properties of Zika virus associated with an epidemic, Yap 
State, Micronesia, 2007. Emerg Infect Dis. 2008;14:1232-
9. PMID: 18680646 DOI: 10.3201/eid1408.080287
Lessler J, Chaisson LH, Kucirka LM, Bi Q, Grantz K, Salje H, 
Carcelen AC, Ott CT, Sheffield JS, Ferguson NM, Cummings 
DA, Metcalf CJ, Rodriguez-Barraquer I. Assessing the glob-
al threat from Zika virus. Science. 2016;353:aaf8160. 
PMID: 27417495 DOI: 10.1126/science.aaf8160
Martins-Melo FR, Lima Mda S, Ramos AN Jr, Alencar CH, 
Heukelbach J. Prevalence of Chagas disease in pregnant 
women and congenital transmission of Trypanosoma cruzi 
in Brazil: a systematic review and meta-analysis. Trop 
Med Int Health. 2014;19:943-57. PMID: 24815954 DOI: 
10.1111/tmi.12328
Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj 
M, Mraz J, Kolenc M, Resman Rus K, Vesnaver Vipot-
nik T, Fabjan Vodušek V, Vizjak A, Pižem J, Petrovec M, 
Avšič Županc T. Zika Virus Associated with Microceph-
aly. N Engl J Med. 2016;374:951-8. PMID: 26862926 
DOI: 10.1056/NEJMoa1600651
Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, 
Shan Yan A, Cao-Lormeau VM, Broult J. Potential for Zika 
virus transmission through blood transfusion demonstrated 
during an outbreak in French Polynesia, November 2013 to 
February 2014. Euro Surveill. 2014;19:pii:20761. PMID: 
24739982 DOI: 10.2807/1560-7917.ES2014.19.14.20761
Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-
Lormeau VM. Potential sexual transmission of Zika virus. 
Emerg Infect Dis. 2015;21:359-61. PMID: 25625872 DOI: 
10.3201/eid2102.141363
Mylonas I. Female genital Chlamydia trachoma-
tis infection: where are we heading? Arch Gyne-
col Obstet. 2012;285:1271-85. PMID: 22350326 
DOI: 10.1007/s00404-012-2240-7
Preece PM, Tookey P, Ades A, Peckham CS. Congenital cy-
tomegalovirus infection: predisposing maternal factors. 
J Epidemiol Community Health. 1986;40:205-9. PMID: 
3021888 DOI: 10.1136/jech.40.3.205
Rao GG, Bacon L, Evans J, Dejahang Y, Michalczyk P, Don-
aldson N; Lewisham Chlamydia and Gonoccoccus Screen-
ing Programme. Prevalence of Neisseria gonorrhoeae in-
fection in young subjects attending community clinics in 
South London. Sex Transm Infect. 2008;84:117-21. PMID: 
17901085 DOI: 10.1136/sti.2007.026914
Valeur-Jensen AK, Pedersen CB, Westergaard T, Jensen 
IP, Lebech M, Andersen PK, Aaby P, Pedersen BN, Melbye 
M. Risk factors for parvovirus B19 infection in pregnan-
cy. JAMA. 1999;281:1099-105. PMID: 10188660 DOI: 
10.1001/jama.281.12.1099
Vargas JE, Allred EN, Leviton A, Holmes LB. Congenital 
microcephaly: phenotypic features in a consecutive sam-
ple of newborn infants. J Pediatr. 2001;139:210-4. PMID: 
11487745 DOI: 10.1067/mpd.2001.115314
Victora CG, Schuler-Faccini L, Matijasevich A, Ribeiro E, 
Pessoa A, Barros FC. Microcephaly in Brazil: how to inter-
pret reported numbers? Lancet. 2016;387:621-4. PMID: 
26864961 DOI: 10.1016/S0140-6736(16)00273-7
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syn-
drome. Lancet. 2016;388:717-27. PMID: 26948435 DOI: 
10.1016/S0140-6736(16)00339-1
Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, 
Luz K. First report of autochthonous transmission of Zika 
virus in Brazil. Mem Inst Oswaldo Cruz. 2015;110:569-72. 
PMID: 26061233 DOI: 10.1590/0074-02760150192
